Increasing Risk of Thrombosis and Emergence of Novel Oral Drugs Drives the Global Anticoagulants Market, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on the Anticoagulants markets. The global market for Anticoagulants is projected to reach US$12.9 billion by the year 2018, primarily driven by growing population at the risk of thrombosis. Aging population, rising incidence of cardiovascular diseases, acute hip and knee complications and the emergence of novel oral therapeutics also comprise the key factors supporting market growth.
San Jose, California (PRWEB) October 29, 2012
Follow us on LinkedIn – With thrombosis emerging as one of the major causes of death in various countries across the world, regulation of blood clotting has become one of the key areas of focus in the medical fraternity in recent times. In this context, various methods of managing the condition have come into the picture namely anti-platelet drugs, anticoagulants, and thrombolytics, with anticoagulants increasingly emerging as the most favored mode of treatment for the disease. Until recently, most of the anticoagulant drugs available in the market were non-oral or injectable agents, with the market limited to only one oral anticoagulant agent, warfarin, which is a vitamin k antagonist available for long-term anticoagulation therapy. But with growing awareness of the limitations of such conventional drugs, efforts were and are still underway for the development of new agents, which display better efficacy and safety profile. Such initiatives have therefore resulted in the emergence of new drugs in the market particularly in the oral segment in recent years, which to a certain extent overcome the drawbacks of older drugs.
Some of the key novel oral anticoagulants launched in the recent past include Xarelto (rivaroxaban) from Bayer/Johnson & Johnson and Pradaxa (dabigatran etexilate) from Boehringer Ingelheim. With growing acceptance and penetration of such drugs, among others which are currently in the development stage or are awaiting approval, the predominance of the traditional heavy weights of the market namely low molecular weight heparins and warfarin, is likely to fade away through the current decade. Representing drug classes of Xa inhibitors and direct thrombin inhibitors, such new drugs have been established to minimize the risk of systemic embolism and stroke in patients with non-valvular atrial fibrillation. With their higher prices and relative ease in administration and superior efficacy and safety profiles, these products, along with products that are in late stage pipeline, are expected to drive the global anticoagulants market, especially in value terms, in the years ahead.
The anticoagulants market has come a long way since the 1990s, when advancements in thrombotic disease detection, increased physician awareness, and vigorous treatment were major drivers for market growth. Growth is presently being led by the arrival of novel therapeutics, complex treatment procedures, patent expiries of first generation drugs, rising competition, as well as demographic settings. Apart from these, the market is also being driven by factors such as rapidly aging population prone to venous and arterial problems and patients on long-term anticoagulation therapies, among others. However, the new drugs in the market, despite their significant advantages, are still far away from becoming standard therapies and are falling short of gaining widespread usage, as physician/patient confidence and cost effectiveness relative to the already available and widely used drugs is yet to be established. Apart from this, lack of availability of antidotes to reverse the effects of such anticoagulants in adverse conditions is hindering the penetration of such drugs in the market, as apprehension prevails among end users targeted to use the drugs.
Even as the new oral drugs are projected to take a majority share of the market, the use of injectable anticoagulants, although on a declining path, would continue to remain reasonably strong through the forecast period, as they would still find usage in critical hospital applications. In a similar manner, while warfarin is expected to lose importance in the market owing to difficulties in its dosing and monitoring, among other factors, it would most likely still hold significance among some sections of the target market, primarily due to its long-track record and low cost advantage as compared to newer drugs.
As stated by the new market research report on Anticoagulants, the US continues to remain the largest as well as the fastest growing regional market, primarily driven by growing incidence of disease conditions such as atrial fibrillation and the introduction and penetration of novel anticoagulant agents. Europe follows the US as the second largest market with future growth likely to emanate from a high level of unmet medical need in coagulation management and influx of novel oral agents. Segment-wise, injectable anticoagulants currently hold a majority share in the market fueled by patients receiving anticoagulation with one or more of the injectable therapies, particularly during general surgery. However, the dominance of the segment is expected to be overtaken in the near term by oral anticoagulants, as new agents in this segment display greater efficacy and have a relatively better safety profile.
Major players profiled in the report include Bayer Healthcare AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd., among others.
The research report titled "Anticoagulants: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, review of new drugs, indications, comparative data on select drugs, drug development pipeline, product approvals/introductions, strategic industry activities and profiles of major companies worldwide. The report provides market estimates and projections in value (US$) for product segments Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) across geographic markets such as the US, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), and Rest of World.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
For the original version on PRWeb visit: http://www.prweb.com/releases/prweboral_anticoagulants/injectable_anticoagulants/prweb10067560.htmView Comments and Join the Discussion!